drugset / Trial / NCT04970667

Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder

NCT04970667

Phase 4 Completed 100 enrolled Peking University Third Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Flupentixol melitracen tablets in the treatment of different types of non random emotional disorders

Timeline

Start
2018-01-01
Primary completion
2020-01-31
Completion
2020-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Flupentixol Unknown
Subject Melitracen Small molecule

Indications